Evidence map›Paper›PMID 40461650›Full record

ArticleScientific reports2025

Anti-amyloidogenic properties of 5‑caffeoylquinic acid-capped selenium nanoparticles.

Shubhangi D Shirsat, Chunyi Li, Zhipeng Liu, Varenyam Achal, Olivier Habimana

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shubhangi D ShirsatBiotechnology and Food Engineering Program, Guangdong Technion-Israel Institute of Technology, Shantou, 515063, China. shubhangi.shirsat@gtiit.edu.cn.
Chunyi LiBiotechnology and Food Engineering Program, Guangdong Technion-Israel Institute of Technology, Shantou, 515063, China.
Zhipeng LiuBiotechnology and Food Engineering Program, Guangdong Technion-Israel Institute of Technology, Shantou, 515063, China.
Varenyam AchalEnvironmental Engineering Program, Guangdong Technion-Israel Institute of Technology, Shantou, 515063, China.
Olivier HabimanaBiotechnology and Food Engineering Program, Guangdong Technion-Israel Institute of Technology, Shantou, 515063, China. olivier.habimana@gtiit.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advancement of neuroprotective pharmacological agents to proficiently avert amyloid-β (Aβ) clustering persists as a significant obstacle in Alzheimer's disease (AD) management. This analysis focuses on the inhibitory characteristics related to amyloid formation of selenium nanoparticles (SeNPs) enveloped in 5-caffeoylquinic acid (CQA), which are biosynthesized using violet sweet potato (PSP) extract. Engineered SeNPs revealed an absorption peak at 260 nm, were spherical and non-crystalline (50-60 nm), and had a zeta potential measured at 24.3 ± 2.1 mV. The antioxidant traits of SeNPs were showcased (IC

Indexed as

Amyloid beta-PeptidesNanoparticlesQuinic AcidSeleniumAcetylcholinesteraseAlzheimer DiseaseAntioxidantsHumansIpomoea batatasMolecular Dynamics SimulationNeuroprotective AgentsAcetylcholinesteraseAmyloid beta-PeptidesAntioxidantscaffeoylquinic acidNeuroprotective AgentsQuinic AcidSelenium5‑caffeoylquinic acidAntioxidantCholinesteraseMolecular dynamic simulationSelenium nanoparticlesβ-Amyloid peptide

Identifiers

PMID40461650
PMCPMC12134378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.